Company Overview of Juventas Therapeutics, Inc.
Juventas Therapeutics, Inc. discovers and develops biopharmaceutical therapies for regenerative medicine. It offers Stromal Derived Factor-1, a therapy that improves cardiac function, as well as enables to protect and repair tissues following organ–damage in pre–clinical disease models. The company also develops biopharmaceuticals that activate the natural repair process that occurs after an injury. In addition, it provides therapies for wound healing and peripheral vascular diseases. Juventas Therapeutics, Inc. was formerly known as AcelleRX Therapeutics, Inc. and changed its name to Juventas Therapeutics, Inc. in April 2009. The company was founded in 2007 and is based in Cleveland, Ohio.
10265 Carnegie Avenue
Cleveland, OH 44106-2130
Founded in 2007
Key Executives for Juventas Therapeutics, Inc.
Chief Executive officer, President and Director
Founder, Chairman of Scientific Advisory Board, Chief Scientific Officer and Chief Medical Officer
Senior Vice President of Finance & Operations
Compensation as of Fiscal Year 2015.
Juventas Therapeutics, Inc. Key Developments
Juventas Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:15 PM
Oct 2 15
Juventas Therapeutics, Inc. Presents at Alliance for Regenerative Medicine Stem Cell Meeting on the Mesa, Oct-07-2015 02:15 PM. Venue: Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037, United States. Speakers: Paul Resnick, Vice President of Business Development.
Juventas Therapeutics, Inc., Receives Fast Track Designation from the U.S. Food and Drug Administration on JVS-100
Jun 16 15
Juventas Therapeutics, Inc. announced that its product candidate, JVS-100, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced ischemic chronic heart failure. The FDA Fast Track process is designed toexpedite the development and review of drugs to treat serious or life-threatening conditions and demonstrate the potential to address unmet medical needs. The FDA has also allowed the protocol for the company's Phase 2b double-blinded, randomized clinical trial of JVS-100 for the treatment of advanced ischemic chronic heart failure in patients with a prior history of heart attack, referred to as STOP-HF2. The STOP-HF2 trial is expected to enroll up to 180 patients at as many as 40 clinical centers in a double-blinded, 1:1 randomized, sham-controlled study evaluating the impact of two administrations of 30mg doses of JVS-100 in heart failure patients with low ejection fraction (less than or equal toÂ 35%) and elevated serum biomarkers (NTproBNPÂ greater than orÂ equal toÂ 500 pg/mL). The first dose will be delivered at the time of patient enrollment and the second will be delivered six months later, each by endomyocardial injection catheter to the left ventricle of the heart.
Juventas Therapeutics, Inc. Appoints James Boland as Independent Director
May 12 15
Juventas Therapeutics, Inc. expanded its Board of Directors to include James Boland as an independent director. Mr. Boland is the retired vice chairman of Ernst & Young and former president, chief executive officer and vice chairman of the Cleveland Cavaliers Operating Company. He currently serves as Chairman of JobsOhio and is on
the Board of the Center for Global Business Studies in Washington D.C.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 4, 2015